Leading pharmaceutical companies are investing heavily in vaccine research, focusing on promising developments from Moderna and Merck. Their experimental cancer vaccine shows encouraging results, while studies indicate that the shingles vaccine may help delay the onset of dementia.
This investment trend occurs despite a challenging political landscape, highlighting the industry's commitment to advancing healthcare solutions and addressing significant medical needs.